Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA3 | P07451 | 3/20 | 0.47 |
| ▸ | CA5A | P35218 | 3/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | CA6 | P23280 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27797412 | 0.87 | PRMT1 (0.48) | CA3CA5ACA5BALDH1A1CYP2C19 | |
| SCHEMBL3483791 | 0.83 | CA3 (0.50) | CA3CA5ACA5BCA12CA2 | |
| SCHEMBL2240590 | 0.83 | CA3 (0.42) | CA3CA5ACA5BCA12CA2 | |
| SCHEMBL18338812 | 0.80 | CA3 (0.54) | CA3CA5ACA5BCA12CA2 | |
| SCHEMBL18544069 | 0.78 | PAOX (0.59) | CA3CA5ACA5BCA12CA2 | |
| SCHEMBL23069642 | 0.78 | CA12 (0.50) | CA3CA5ACA5BCA12CA2 | |
| SCHEMBL13756331 | 0.77 | CASP2 (0.59) | CA3CA5ACA5BCA12CA2 | |
| SCHEMBL8700485 | 0.77 | PAOX (0.44) | CA3CA5ACA5BCA12CA2 | |
| SCHEMBL8519355 | 0.76 | CA5B (0.55) | CA3CA5ACA5BCA12CA2 | |
| SCHEMBL8519208 | 0.76 | CA5B (0.55) | CA3CA5ACA5BCA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114763336-A | Production method of atazanavir sulfate crystal form | 威智医药有限公司 | 2022-07-19 | — | — | CN | disclosed |
| US-20170136001-A1 | METHOD OF TREATING A VIRAL INFECTION USING ELVITEGRAVIR COMBINATIONS | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20100331331-A1 | THERAPEUTIC COMPOSITIONS AND THE USE THEREOF | THERAPEUTIC COMPOSITONS AND USE THEREOF (CA) | 2010-12-30 | — | — | US | disclosed |
| EP-2167088-A1 | THERAPEUTIC COMPOSITIONS AND THE USE THEREOF | Gilead Sciences, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090093467-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | GILEAD SCIENCES, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2009006199-A1 | THERAPEUTIC COMPOSITIONS AND THE USE THEREOF | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2008156632-A1 | AZAPEPTIDE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331331-A1 | THERAPEUTIC COMPOSITIONS AND THE USE THEREOF | CYP3A43, CYP27A1, CYP7A1 | CA3 3345/4885CA5A 317/4885CA5B 372/4885 |
| US-20170136001-A1 | METHOD OF TREATING A VIRAL INFECTION USING ELVITEGRAVIR COMBINATIONS | CYP3A43, CYP3A7, CYP3A5 | CA3 2810/4885CA5A 537/4885CA5B 332/4885 |
| US-20090093467-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | CYP3A43, CYP7A1, CYP27A1 | CA3 2305/4885CA5A 286/4885CA5B 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.